National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 519504

Case Details

VAERS ID: 519504 (history)  
Age:   
Gender: Female  
Location: Foreign  
Vaccinated:2009-01-27
Onset:2009-02-01
   Days after vaccination:5
Submitted: 2014-01-15
   Days after onset:1809
Entered: 2014-01-15
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 1 UN / IM

Administered by: Other       Purchased by: Other
Symptoms: Asthenia, Blood test normal, Colour blindness, Diplopia, Dysaesthesia, Fatigue, Gait disturbance, Hemiparesis, Hypoaesthesia, Lumbar puncture abnormal, Multiple sclerosis, Muscle spasms, Neuralgia, Nuclear magnetic resonance imaging brain abnormal, Optic neuritis, Pain, Papillitis, Paraesthesia, Polymerase chain reaction, Sensory disturbance, Sleep disorder, Urinary tract disorder, Visual acuity reduced, Visual acuity tests abnormal, White matter lesion
SMQs:, Peripheral neuropathy (narrow), Anticholinergic syndrome (broad), Congenital, familial and genetic disorders (narrow), Embolic and thrombotic events, vessel type unspecified and mixed arterial and venous (narrow), Dystonia (broad), Parkinson-like events (broad), Guillain-Barre syndrome (broad), Noninfectious encephalitis (broad), Glaucoma (broad), Optic nerve disorders (narrow), Demyelination (narrow), Lens disorders (broad), Retinal disorders (narrow), Conditions associated with central nervous system haemorrhages and cerebrovascular accidents (narrow), Ocular infections (broad), Ocular motility disorders (broad), Hypoglycaemia (broad)

Life Threatening? No
Died? No
Permanent Disability? Yes
Recovered? No
ER or Doctor Visit? Yes
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: ZOLDORM
Current Illness: Sleep disorder; Immunisation
Preexisting Conditions: 11/18/2008, GARDASIL, Immunisation
Diagnostic Lab Data: On 25 May 2009: the visual acuity of the left eye was measured at 0.05/10. The rest of the neurologic status was without abnormality. Lumbar puncture performed on 25 May 2009: pleocytosis (62/mm3) with proteinorrachia in the standard and intrathecal synthesis of IgG oligoclonal bands. MRI brain performed on 28 May 2009: showed a decade of lesions of the white matter with right frontal lesion. PCR and blood test (date not reported): were negative for infectious agents or antinuclear antibodies. MRI performed on 01-Sep-2009: the decade of white matter lesions were still present, showed three new left frontal lesions (right frontal lesion disappeared), one right temporal lesion, and two lesions of the left anterolateral part of the spine up to
CDC Split Type: WAES1401CHE005672

Write-up: Information has been received from Sanofi Pasteur MSD (manufacturer control # CH-1577272925-E2014-00151) on 08-JAN-2014. Case reported by a consumer to the Health Authorities on 08-Jan-2014 under the reference number 2013-06444. Case not medically confirmed. A female patient (weight and height not reported) had received a second dose of GARDASIL (batch number not reported) on 27-Jan-2009 via intramuscular route (site of administration not reported). The patient''s medical history included medication with contraceptives (several pills prescribed, registered trademarks unknown) since 2009. The patient had no other health disorder. The patient received a first dose of GARDASIL (batch number not reported) on 18-Nov-2008. The patient''s family medical history included a case of multiple sclerosis on one of the twin sons of the maternal great aunt of the patient. The patient''s mother reported that her daughter experienced burn-like pains and numbness in arms and legs since Feb-2009, some weeks after the second dose of GARDASIL administration, which occurred intermittently within the following months and which not responded well to anti-inflammatory medications. The mother make the link between vaccination and the daughter''s symptoms after seeing a TV show related to a complaint initiated by a patient diagnosed with multiple sclerosis and who experienced the first symptoms of the disease after a vaccination with GARDASIL. On 25 May 2009, the patient was hospitalised for a left optic neuritis. The first symptoms occurred on 22 May 2009 (progressive decrease of visual acuity, disturbed vision of colors). The visual acuity of the left eye was measured at 0.05/10. The rest of the neurologic status was without abnormality. Corticotherapy IV was administered to the patient, leading to an important improvement of visual acuity. Other exams performed (brain MRI and cerebrospinal fluid analysis) were compatible with an inflammatory condition, but nothing could be concluded. A control exam (MRI, in neurologic consultation) was scheduled at 3 months. The brain MRI performed on 01-Sep-2009 was compatible with a progression of inflammatory lesions of the white matter. Diagnostic criteria for a multiple sclerosis were present. The evolution was defined by remission and relapse of the disease. A second flare occurred on 07-Sep-2009: the patient experienced legs hypoesthesia with strength loss and walking disturbances, and diplopia on 17-Sep-2009. A third flare on Dec-2009 was characterized by a right very moderate papillitis. A fourth flare probably in Jun-2010 was characterized by sensory troubles. A fifth flare occurred in Aug 2010, with crural-brachial-facial dysesthesia and hypoesthesia, urinary symptoms and fatigue. No other flare was reported since then. The details concerning the motor, sensory and visual symptoms during these years were not provided but the neurologic status performed on May-2012, far away from the last flare, showed no real strength loss or sensory troubles. There were pains like sensations of burn and "needles in the back", at the level of the lower limbs and palmar sides of the hands. These pains were described at the time of the reporting as omnipresent, with strong exacerbations episodes, and were associated with spasms, occurring during the night in arms and legs. The ophthalmologic control performed on 12-May-2010, during optic neuritis and papillitis episodes, showed a visual function on the upper limit of the normal on both sides. The patient received the following therapies: IV corticotherapy during flares, (REBIF, 44 micrograms, via subcutaneous route, 3 times per week from 14-Oct-2009 to Mar-2013), which was replaced by TYSABRI (started on 30-Mar-2013), GILENYA (started since the mid of 2013). The treatment for the pain of intermittent symptoms included SAROTEN (since Dec-2009), and NEURONTIN (since Apr-2010, due to aggravation of paroxystic symptoms like left facial hemiparesia). The patient also received for sl


New Search

Link To This Search Result:

http://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=519504


Copyright © 2017 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166